Protagenic Therapeutics Stock One Year Return
PTIX Stock | USD 0.27 0 0.74% |
Protagenic Therapeutics fundamentals help investors to digest information that contributes to Protagenic Therapeutics' financial success or failures. It also enables traders to predict the movement of Protagenic Stock. The fundamental analysis module provides a way to measure Protagenic Therapeutics' intrinsic value by examining its available economic and financial indicators, including the cash flow records, the balance sheet account changes, the income statement patterns, and various microeconomic indicators and financial ratios related to Protagenic Therapeutics stock.
Protagenic | One Year Return |
Protagenic Therapeutics Company One Year Return Analysis
Protagenic Therapeutics' One Year Return is the annualized return generated from holding a security for exactly 12 months. The measure is considered to be good short-term measures of fund performance. In other words, it represents the capital appreciation of fund investments over the last year. However when the market is volatile such as in recent years, One Year Return measure can be misleading.
More About One Year Return | All Equity Analysis
One Year Return | = | (Mean of Monthly Returns - 1) | X | 100% |
Protagenic One Year Return Driver Correlations
Understanding the fundamental principles of building solid financial models for Protagenic Therapeutics is extremely important. It helps to project a fair market value of Protagenic Stock properly, considering its historical fundamentals such as One Year Return. Since Protagenic Therapeutics' main accounts across its financial reports are all linked and dependent on each other, it is essential to analyze all possible correlations between related accounts. However, instead of reviewing all of Protagenic Therapeutics' historical financial statements, investors can examine the correlated drivers to determine its overall health. This can be effectively done using a conventional correlation matrix of Protagenic Therapeutics' interrelated accounts and indicators.
Click cells to compare fundamentals
Although One Year Fund Return indicator can give a sense of overall fund short-term potential, it is recommended to look at mid and long term return measure before selecting a particular fund or ETF. The great way to validate fund short-term performance is to compare it with other similar funds or ETFs for the same 12 months interval.
Competition |
Protagenic Return On Tangible Assets
Return On Tangible Assets |
|
Based on the recorded statements, Protagenic Therapeutics has an One Year Return of 0.0%. This indicator is about the same for the Biotechnology average (which is currently at 0.0) sector and about the same as Health Care (which currently averages 0.0) industry. This indicator is about the same for all United States stocks average (which is currently at 0.0).
Protagenic One Year Return Peer Comparison
Stock peer comparison is one of the most widely used and accepted methods of equity analyses. It analyses Protagenic Therapeutics' direct or indirect competition against its One Year Return to detect undervalued stocks with similar characteristics or determine the stocks which would be a good addition to a portfolio. Peer analysis of Protagenic Therapeutics could also be used in its relative valuation, which is a method of valuing Protagenic Therapeutics by comparing valuation metrics of similar companies.Protagenic Therapeutics is currently under evaluation in one year return category among its peers.
Protagenic Therapeutics Current Valuation Drivers
We derive many important indicators used in calculating different scores of Protagenic Therapeutics from analyzing Protagenic Therapeutics' financial statements. These drivers represent accounts that assess Protagenic Therapeutics' ability to generate profits relative to its revenue, operating costs, and shareholders' equity. Below are some of Protagenic Therapeutics' important valuation drivers and their relationship over time.
2020 | 2021 | 2022 | 2023 | 2024 | 2025 (projected) | ||
Enterprise Value | 22.7M | 24.1M | 20.2M | 3.0M | 2.7M | 3.9M |
Protagenic Fundamentals
Return On Equity | -2.06 | ||||
Return On Asset | -0.9 | ||||
Current Valuation | (2.91 M) | ||||
Shares Outstanding | 6.79 M | ||||
Shares Owned By Insiders | 14.24 % | ||||
Shares Owned By Institutions | 5.76 % | ||||
Number Of Shares Shorted | 44.86 K | ||||
Price To Earning | 9.43 X | ||||
Price To Book | 2.70 X | ||||
EBITDA | (4.5 M) | ||||
Net Income | (5 M) | ||||
Cash And Equivalents | 8.87 M | ||||
Cash Per Share | 0.51 X | ||||
Total Debt | 655.25 K | ||||
Debt To Equity | 0.04 % | ||||
Current Ratio | 19.47 X | ||||
Book Value Per Share | 0.83 X | ||||
Cash Flow From Operations | (3.7 M) | ||||
Short Ratio | 1.33 X | ||||
Earnings Per Share | (1.27) X | ||||
Target Price | 4.0 | ||||
Beta | 0.25 | ||||
Market Capitalization | 4.04 M | ||||
Total Asset | 4.32 M | ||||
Retained Earnings | (30.78 M) | ||||
Working Capital | 3.54 M | ||||
Current Asset | 3.75 M | ||||
Current Liabilities | 736 K | ||||
Net Asset | 4.32 M |
About Protagenic Therapeutics Fundamental Analysis
The Macroaxis Fundamental Analysis modules help investors analyze Protagenic Therapeutics's financials across various querterly and yearly statements, indicators and fundamental ratios. We help investors to determine the real value of Protagenic Therapeutics using virtually all public information available. We use both quantitative as well as qualitative analysis to arrive at the intrinsic value of Protagenic Therapeutics based on its fundamental data. In general, a quantitative approach, as applied to this company, focuses on analyzing financial statements comparatively, whereas a qaualitative method uses data that is important to a company's growth but cannot be measured and presented in a numerical way.
Please read more on our fundamental analysis page.
Also Currently Popular
Analyzing currently trending equities could be an opportunity to develop a better portfolio based on different market momentums that they can trigger. Utilizing the top trending stocks is also useful when creating a market-neutral strategy or pair trading technique involving a short or a long position in a currently trending equity.Additional Tools for Protagenic Stock Analysis
When running Protagenic Therapeutics' price analysis, check to measure Protagenic Therapeutics' market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Protagenic Therapeutics is operating at the current time. Most of Protagenic Therapeutics' value examination focuses on studying past and present price action to predict the probability of Protagenic Therapeutics' future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Protagenic Therapeutics' price. Additionally, you may evaluate how the addition of Protagenic Therapeutics to your portfolios can decrease your overall portfolio volatility.